248 related articles for article (PubMed ID: 27910966)
1. Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
Vertès A
Drugs Today (Barc); 2016 Oct; 52(10):577-583. PubMed ID: 27910966
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing road map for tissue engineering and regenerative medicine technologies.
Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
[TBL] [Abstract][Full Text] [Related]
3. Global strategic partnerships in regenerative medicine.
French A; Suh JY; Suh CY; Rubin L; Barker R; Bure K; Reeve B; Brindley DA
Trends Biotechnol; 2014 Sep; 32(9):436-40. PubMed ID: 25150363
[TBL] [Abstract][Full Text] [Related]
4. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
Cho E; Yoo SL; Kang Y; Lee JH
Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
[TBL] [Abstract][Full Text] [Related]
5. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
6. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
7. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
8. Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells.
Mittra J; Tait J; Mastroeni M; Turner ML; Mountford JC; Bruce K
N Biotechnol; 2015 Jan; 32(1):180-90. PubMed ID: 25094050
[TBL] [Abstract][Full Text] [Related]
9. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
Rose JB; Williams DJ
Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
[TBL] [Abstract][Full Text] [Related]
10. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
Plagnol AC; Rowley E; Martin P; Livesey F
Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
[TBL] [Abstract][Full Text] [Related]
11. Update on Regulation of Regenerative Medicine in Taiwan.
Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
[TBL] [Abstract][Full Text] [Related]
12. Regenerative medicine in India: trends and challenges in innovation and regulation.
Tiwari SS; Raman S; Martin P
Regen Med; 2017 Oct; 12(7):875-885. PubMed ID: 29111891
[TBL] [Abstract][Full Text] [Related]
13. Distributive justice and regenerative medicine.
Gardner J
Regen Med; 2017 Oct; 12(7):865-874. PubMed ID: 29095111
[TBL] [Abstract][Full Text] [Related]
14. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
[TBL] [Abstract][Full Text] [Related]
15. A Path Forward for Regenerative Medicine.
Fanaroff AC; Morrow V; Krucoff MW; Seltzer JH; Perin EC; Taylor DA; Miller LW; Zeiher AM; Fernández-Avilés F; Losordo DW; Henry TD; Povsic TJ
Circ Res; 2018 Aug; 123(4):495-505. PubMed ID: 30355250
[TBL] [Abstract][Full Text] [Related]
16. Stem cell industry update: 2012 to 2016 reveals accelerated investment, but market capitalization and earnings lag.
Ng M; Song S; Piuzzi NS; Ng K; Gwam C; Mont MA; Muschler GF
Cytotherapy; 2017 Oct; 19(10):1131-1139. PubMed ID: 28807603
[TBL] [Abstract][Full Text] [Related]
17. Emphasizing the need to more fully understand development: a stem cells and regenerative medicine meeting report.
Chang AI; Appasani K
J Tissue Eng Regen Med; 2007; 1(4):274-80. PubMed ID: 18038417
[TBL] [Abstract][Full Text] [Related]
18. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
Bock AJ; Johnson D
Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
[TBL] [Abstract][Full Text] [Related]
19. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
Mahalatchimy A; Faulkner A
Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
[TBL] [Abstract][Full Text] [Related]
20. 2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.
Vertès A
IDrugs; 2010 Dec; 13(12):819-21. PubMed ID: 21154132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
